Physician profile
Jill Kalman
NPI 1528034352
$189,326.36
in general payments reported to CMS, 2019-2025
3 companies · $162K in 2025
The $162K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $3,846 · 2023: $132 · 2024: $23K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $162K · Consulting Fee: $23K · Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $161,988.36 |
| Consulting Fee | $23,000.00 |
| Food and Beverage | $271.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Longeviti Neuro Solutions INC | $189,054.61 | 2021-2025 | Clearfit |
| Insightec,INC | $255.79 | 2023-2024 | Exablate |
| Amgen INC. | $15.96 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.03 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Kalman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.